SEC Form 4 · accession 0001193125-26-282740
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Filip Janku
Officer — Chief Medical Officer
Period of report
Jun 23, 2026
Accepted (ET)
Jun 25, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 23, 2026 | M | 6,000 | $7.56 | A | 71,837 | D | |
| Common StockF2 | Jun 23, 2026 | S | 11,845 | $20.2214 | D | 59,992 | D | |
| Common Stock | Jun 24, 2026 | M | 30,000 | $7.56 | A | 89,992 | D | |
| Common StockF3 | Jun 24, 2026 | S | 30,000 | $21.4227 | D | 59,992 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $7.56 | Jun 23, 2026 | M | 6,000 | D | — | Oct 3, 2032 | Common Stock | 6,000 | 96,000 | D |
| Stock Option (Right to Buy)F4 | $7.56 | Jun 24, 2026 | M | 30,000 | D | — | Oct 3, 2032 | Common Stock | 30,000 | 66,000 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The shares underlying this option are fully vested and exercisable.
Remarks
Exhibit 24.2 - Substitute Power of Attorney